Ignite Creation Date:
2024-07-17 @ 10:49 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06481956
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-07-01
First Post:
2024-06-25
Brief Title:
T-DM1 Combined With CDK46 Inhibitor Ribociclib
Sponsor:
Zheng Yabing
Organization:
Zhejiang Cancer Hospital
Study Overview
Official Title:
Phase II Clinical Study of Trastuzumab Emtansine T-DM1 Combined With Cyclin-dependent Kinase 46 CDK46 Inhibitor Ribociclib in the Treatment of Human Epidermal Growth Factor Receptor-2 HER2-Positive Advanced Breast Cancer
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To explore the efficacy and safety of T-DM1 combined with CDK46 inhibitor Ribociclib in the treatment of HER2-positive advanced breast cancer
Detailed Description:
This is a multicenter single-armPhase II clinical trial to explore the efficacy and safety of Trastuzumab Emtansine T-DM1 combined with CDK46 inhibitor Ribociclib in the treatment of unresectable locally advanced or metastatic HER2-positive breast cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None